INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 194 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.35 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $0 | – | 10 | -23.1% | 0.00% | – |
| Q3 2021 | $0 | -100.0% | 13 | -92.1% | 0.00% | – |
| Q2 2021 | $3,000 | -88.0% | 165 | -84.9% | 0.00% | – |
| Q1 2021 | $25,000 | +525.0% | 1,096 | +564.2% | 0.00% | – |
| Q4 2020 | $4,000 | -42.9% | 165 | 0.0% | 0.00% | – |
| Q3 2020 | $7,000 | -12.5% | 165 | 0.0% | 0.00% | – |
| Q2 2020 | $8,000 | -57.9% | 165 | -41.1% | 0.00% | -100.0% |
| Q3 2019 | $19,000 | +216.7% | 280 | +460.0% | 0.00% | – |
| Q3 2018 | $6,000 | – | 50 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
| CM Management, LLC | 45,000 | $668,000 | 0.50% |
| EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
| DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
| Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
| GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
| Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
| ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
| Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
| DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |